Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, An Important New…
We recommend: no prescription levitra, atomoxetine with no prescription, viagra with no prescription
Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry
e-mail to a champion pressman well-disposed aspect / pen opinions
Santaris Pharma A/S, a clinical-stage biopharmaceutical troupe focussed on the find and evolution of RNA-targeted therapies, proclaimed that it has forward-looking into dose exploitation a uncovering inquiry nominee directed against PCSK9 (proprotein convertase subtilisin/kexin character 9), an significant new quarry for the handling of highschool cholesterin . Using its proprietorship Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and innovative the new dose, SPC5001, in just 18 months.
High cholesterin is a major hazard element for coronary spirit disease , nerve tone-beginning and solidus . According to the World Health Organization, highschool cholesterin is estimated to effort 18% of strokes and 56% of pump disease, globally and amounts to some 4.4 gazillion deaths and 40.4 jillion disability-adjusted sprightliness years(1).
Santaris Pharma A/S presented presymptomatic information on SPC5001 finish month at the PCSK9 Conference “From factor to therapeutics” in Nantes, France where many top pharmaceutic companies collected to discourse efforts to acquire therapies aimed at inhibiting the crucial new quarry PCSK9, a protein convoluted in regulation LDL (low-density lipoprotein) or “bad” cholesterin in the descent.
Data presented by Santaris Pharma A/S scientists showed that SPC5001 provided powerful, particular and durable prohibition of PCSK9 and lowered signify LDL cholesterin by 50% in non-human primates with a sustained reducing of 74% in the highest answerer. SPC5001 did not alteration HDL (high-density lipoprotein) levels or the “effective” cholesterin in the origin(2). The presymptomatic information propose that SPC5001 has the potency to supply patients with a new discussion selection in managing their cholesterin levels.
“There is a lot of sake in PCSK9 as an exciting new object for the discourse of mellow cholesterin and having demonstrated that SPC5001 efficaciously lowers LDL or the ‘bad’ cholesterin in presymptomatic studies, we are quick moving ahead with plans to feeler SPC5001 into clinical studies as a likely new intervention to assistance patients wagerer deal the risks of cardiovascular diseases,” aforesaid Henrik Orum, PhD, Vice President and Chief Scientific Officer of Santaris Pharma A/S. “SPC5001 is a will to the efficiency of our LNA Drug Platform and Drug Discovery Engine as we observed, optimized and modern SPC5001 into presymptomatic exploitation in just 18 months.”
The LNA Drug Platform and Drug Discovery Engine highly-developed by Santaris Pharma A/S combines the Company’s proprietorship LNA alchemy with its extremely specialised and targeted dose maturation capabilities to chop-chop pitch stiff single-stranded LNA-based dose candidates for a orbit of diseases including metabolous disorders, infective and incitive diseases, cancer and rarified genetical disorders.
“In plus to forward SPC5001 into dose maturation for the intervention of eminent cholesterin, we stay on rail to get Phase 2 clinical trials of miravirsen (SPC3649) in patients with Hepatitis C in the indorsement one-half of this year,” aforesaid Soren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. “In our home programs and partnered programs, the versatility and unsubtle usefulness of Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine continues to be vital in development efficient RNA-targeted therapies with highschool kinship, mark specificity and singular authorisation for a compass of diseases.”
SPC5001 adds to the portfolio of Santaris Pharma A/S drugs in growth, including its virtually sophisticated colonial miravirsen, the International Nonproprietary Name (INN) or generic diagnose for the deepen once known as SPC3649.
Miravirsen, the get-go microRNA-targeted dose to introduce humming clinical trials, is a particular inhibitor of miR-122, a liver-specific microRNA that the Hepatitis C virus requires for rejoinder. Unlike Hepatitis C therapies that straight mark the virus, miravirsen deeds by removing a “assistant” corpuscle (miR-122) that the virus necessarily in rescript to pee-pee new copies. Miravirsen is existence studied in a Phase 1 test multiple-ascending battery-acid sketch in hefty volunteers and a Phase 2 cogitation in patients septic with Hepatitis C is expected to get in the s one-half of 2010.
Santaris Pharma A/S besides has a unsubtle reach of dose find and ontogenesis programs with its partners: Shire plc (lead-in candidates against up to fin targets for rarified transmissible disorders), Pfizer (lede candidates against up to ten targets), GlaxoSmithKline (options to dose candidates from up to foursome viral disease programs) and Enzon Pharmaceuticals (lede candidates against 8 cancer targets successfully delivered).
The LNA Drug Platform utilizing Santaris Pharma A/S proprietorship LNA alchemy provides the key to delivering on the call of RNA-targeted therapies tod by addressing these concerns and overcoming the limitations of sooner antisense and siRNA technologies to birth strong single-stranded LNA-based dose candidates crossways a concourse of disease states. The unequalled compounding of diminished sizing and real gamey kinship, which is lonesome accomplishable with LNA-based drugs, allows this new year of drugs to powerfully and specifically suppress RNA-targets in many unlike tissues without the pauperism for composite deliverance vehicles. LNA-based drugs are a hopeful new character of therapy that enables scientists to produce drugs to onset antecedently unaccessible clinical pathways. The well-nigh crucial features of LNA-based drugs admit splendid specificity, providing optimum targeting; increased kinship to targets providing improved effectiveness, and solid pharmacology upon systemic deliverance without complicated bringing vehicles.
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical fellowship focussed on the uncovering and growing of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine highly-developed by Santaris Pharma A/S blend the Company’s proprietorship LNA alchemy with its extremely specialised and targeted dose exploitation capabilities to speedily present stiff single-stranded LNA-based dose candidates crosswise a throng of disease states. The Company’s inquiry and growing activities nidus on infective diseases and metabolous disorders, patch partnerships with major pharmaceutic companies admit a reach of cure areas including cancer, infective and rabble-rousing diseases, and rarified hereditary disorders. The Company has strategical partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Pfizer and Shire plc. As contribution of its all-embracing plain acres, the Company holds undivided universal rights to all alterative uses of LNAs. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.
(2) Oral and placard display PCSK9 Conference, Locked Nucleic Acid antisense oligonucleotide suppression of PCSK9, March 11, 2010
Any aesculapian data promulgated on this site is not intended as a reserve for informed aesculapian advice and you should not takings any accomplish earlier consulting with a wellness guardianship master. For more entropy, delight scan our price and weather .
For any corrections of actual entropy, or to touch the editors delight use our feedback mannikin .
Please beam any aesculapian tidings or wellness newsworthiness pressure releases to:
Personalized Homepage Weekly Newsletters Daily News Alerts
What Is…
Hemoheart Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Parkinson’s Disease Stem Cells All ‘What Is…’ Articles
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us
Cholesterol Forum Discuss issues relating to cholesterin in our new assembly.
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, An Important New Target For The Treatment Of High Cholesterol
Higher Consumption Of Dietary Added Sugars Associated With Unfavorable Cholesterol And Triglyceride Levels
Atherotech Targets Heart Disease At Internal Medicine 2010 With VAP(R) Cholesterol Test
View more newsworthiness…
These are the nigh take articles from this intelligence class for the close 6 months:
High ancestry fat levels usually acclivity the cholesterin values in the origin, which in routine elevates the danger of atherosclerosis and spunk blast. Now a new work from Lund University in Sweden shows that butter leads to…
Statins Show Dramatic Drug And Cell Dependent Effects In The Brain
Studies Negate Concerns That Low Cholesterol Leads To Some Cancers
Patients With High CRP And Normal LDL Have Long-Term Risk For Heart Disease, Stroke And Death
Follow Our News On Twitter:
Get the modish tidings for this family delivered heterosexual to your Twitter story. Simply dog the tie-in under and quality the ‘accompany’ choice.
Each year more than a 1000000 Americans sustain pump attacks. High cholesterin can cast a occlusion in the arteries and lede to mettle disease. Lifestyle changes and adhesiveness to a handling program are authoritative for cholesterin direction…
Elevated cholesterin can come as a english gist from HIV treatments. Hear how one soul with HIV stairs up to the gainsay of acquiring his cholesterin devour…
View more videos…
Today besellers: cialis with no prescription, levitra with no prescription, aciphex with no prescription
Leave a Reply